These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 18709512)
21. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Strosberg JR; Choi J; Cantor AB; Kvols LK Cancer Control; 2006 Jan; 13(1):72-8. PubMed ID: 16508629 [TBL] [Abstract][Full Text] [Related]
22. 31P MR spectroscopy to evaluate the efficacy of hepatic artery embolization in the treatment of neuroendocrine liver metastases. Ljungberg M; Westberg G; Vikhoff-Baaz B; Starck G; Wängberg B; Ekholm S; Ahlman H; Forssell-Aronsson E Acta Radiol; 2012 Dec; 53(10):1118-26. PubMed ID: 23051638 [TBL] [Abstract][Full Text] [Related]
23. Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases? Hung JS; Chang MC; Lee PH; Tien YW World J Surg; 2007 Dec; 31(12):2392-7. PubMed ID: 17960455 [TBL] [Abstract][Full Text] [Related]
24. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. Dong XD; Carr BI Med Oncol; 2011 Dec; 28 Suppl 1():S286-90. PubMed ID: 21107755 [TBL] [Abstract][Full Text] [Related]
25. Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice. Grozinsky-Glasberg S; Kaltsas G; Kaltsatou M; Lev-Cohain N; Klimov A; Vergadis V; Uri I; Bloom AI; Gross DJ Endocrine; 2018 Jun; 60(3):499-509. PubMed ID: 29383678 [TBL] [Abstract][Full Text] [Related]
26. Hepatic arterial embolization in patients with neuroendocrine tumors. Del Prete M; Fiore F; Modica R; Marotta V; Marciello F; Ramundo V; Di Sarno A; Carratù A; di Roseto Cde L; Tafuto S; Tatangelo F; Baldelli R; Colao A; Faggiano A; J Exp Clin Cancer Res; 2014 May; 33(1):43. PubMed ID: 24887262 [TBL] [Abstract][Full Text] [Related]
27. Predictors of response to radio-embolization (TheraSphere®) treatment of neuroendocrine liver metastasis. Shaheen M; Hassanain M; Aljiffry M; Cabrera T; Chaudhury P; Simoneau E; Kongkaewpaisarn N; Salman A; Rivera J; Jamal M; Lisbona R; Khankan A; Valenti D; Metrakos P HPB (Oxford); 2012 Jan; 14(1):60-6. PubMed ID: 22151453 [TBL] [Abstract][Full Text] [Related]
28. Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival. Chen JX; Rose S; White SB; El-Haddad G; Fidelman N; Yarmohammadi H; Hwang W; Sze DY; Kothary N; Stashek K; Wileyto EP; Salem R; Metz DC; Soulen MC Cardiovasc Intervent Radiol; 2017 Jan; 40(1):69-80. PubMed ID: 27738818 [TBL] [Abstract][Full Text] [Related]
29. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Perry LJ; Stuart K; Stokes KR; Clouse ME Surgery; 1994 Dec; 116(6):1111-6; discussion 1116-7. PubMed ID: 7985095 [TBL] [Abstract][Full Text] [Related]
30. Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver. Gaur SK; Friese JL; Sadow CA; Ayyagari R; Binkert CA; Schenker MP; Kulke M; Baum R Cardiovasc Intervent Radiol; 2011 Jun; 34(3):566-72. PubMed ID: 21431978 [TBL] [Abstract][Full Text] [Related]
31. Laparoscopic debridement of hepatic necrosis after hepatic artery chemoembolization. Tejirian T; Heaney A; Colquhoun S; Nissen N JSLS; 2007; 11(4):493-5. PubMed ID: 18237517 [TBL] [Abstract][Full Text] [Related]
32. Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications. Lewis MA; Jaramillo S; Roberts L; Fleming CJ; Rubin J; Grothey A Oncologist; 2012; 17(5):725-31. PubMed ID: 22511263 [TBL] [Abstract][Full Text] [Related]
33. Hepatic surgery for metastases from neuroendocrine tumors. Sarmiento JM; Que FG Surg Oncol Clin N Am; 2003 Jan; 12(1):231-42. PubMed ID: 12735141 [TBL] [Abstract][Full Text] [Related]
34. Role of interventional radiology in the treatment of patients with neuroendocrine metastases in the liver. Kvols LK; Turaga KK; Strosberg J; Choi J J Natl Compr Canc Netw; 2009 Jul; 7(7):765-72. PubMed ID: 19635229 [TBL] [Abstract][Full Text] [Related]
35. Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin. Sommer WH; Ceelen F; García-Albéniz X; Paprottka PM; Auernhammer CJ; Armbruster M; Nikolaou K; Haug AR; Reiser MF; Theisen D Eur Radiol; 2013 Nov; 23(11):3094-103. PubMed ID: 23807569 [TBL] [Abstract][Full Text] [Related]
36. Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome. Swärd C; Johanson V; Nieveen van Dijkum E; Jansson S; Nilsson O; Wängberg B; Ahlman H; Kölby L Br J Surg; 2009 May; 96(5):517-21. PubMed ID: 19358175 [TBL] [Abstract][Full Text] [Related]
37. Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases. Swierz MJ; Storman D; Riemsma RP; Wolff R; Mitus JW; Pedziwiatr M; Kleijnen J; Bala MM Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009498. PubMed ID: 32163181 [TBL] [Abstract][Full Text] [Related]
38. Transarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastases. Riemsma RP; Bala MM; Wolff R; Kleijnen J Cochrane Database Syst Rev; 2013 Apr; (4):CD009498. PubMed ID: 23633373 [TBL] [Abstract][Full Text] [Related]